Arcus Biosciences RCUS Business Segments — Compensation and personnel costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's business segments — compensation and personnel costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's business segments — compensation and personnel costs?
- Arcus Biosciences (RCUS) reported business segments — compensation and personnel costs of $70M in Q1 2026.
- How has Arcus Biosciences's business segments — compensation and personnel costs changed year-over-year?
- Arcus Biosciences's business segments — compensation and personnel costs increased by 6.1% year-over-year, from $66M to $70M.
- What is the long-term trend for Arcus Biosciences's business segments — compensation and personnel costs?
- Over 3 years (2022 to 2025), Arcus Biosciences's business segments — compensation and personnel costs has grown at a 8.9% compound annual growth rate (CAGR), from $189M to $244M.
- What does business segments — compensation and personnel costs mean?
- Includes all salaries, benefits, stock-based compensation, and related expenses for employees dedicated to the reportable segment. It serves as a primary measure of the human capital investment required to sustain research, development, and operational activities.